๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Impact of phase II trials with progression-free survival as end-points on survival-based phase III studies in patients with anaplastic gliomas

โœ Scribed by Victor A Levin; Sandra Ictech; Kenneth R Hess


Book ID
115010991
Publisher
BioMed Central
Year
2007
Tongue
English
Weight
343 KB
Volume
7
Category
Article
ISSN
1471-2407

No coin nor oath required. For personal study only.


๐Ÿ“œ SIMILAR VOLUMES


A VM 26-based regimen for patients with
โœ Leo I. Gordon; Janet Andersen; Stephanie Gregory; Joseph Mazza; Paul Chervenick; ๐Ÿ“‚ Article ๐Ÿ“… 1993 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 545 KB

Background. The epidophyllotoxin VM 26 has been shown to have single-agent activity in patients with diffuse aggressive lymphoma. In an attempt to determine its activity in combination with other agents known to be effective in lymphoma, a Phase I1 trial of a novel chemotherapy regimen was conducted